Physician profile

Jesse Selber

Plastic Surgery · Royal Oak, MI

NPI 1417013384

$180,562.77

in general payments reported to CMS, 2019-2025

37 companies · $20K in 2025

The $20K reported for 2025 was more than what 97% of Plastic Surgery providers received nationally (typical 2025 total: $380).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$52,368.40
Food and Beverage$12,840.60
Travel and Lodging$6,792.52
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program$600.00
Gift$14.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Integra Lifesciences Corporation $112,631.87 2019-2025 Integra, Omnigraft, Surgimend
Medical Microinstruments, INC. $24,358.46 2024 Symani Surgical Sistem, Symani Surgical Systems
Intuitive Surgical, INC. $17,072.49 2019-2025 Da Vinci Surgical System
Tela Bio, INC. $5,161.14 2019-2025 Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex)
Tei Biosciences INC $3,736.64 2019
Mentor Worldwide LLC $2,786.79 2019-2025 Mentor Memorygel Resterilizable Gel Sizer, Mentor Cpx 2 Breast Tissue Expander
Allergan, INC. $2,603.11 2019-2022
Musculoskeletal Transplant Foundation INC. $1,980.30 2020-2025
Zimmer Biomet Holdings, INC. $1,669.59 2019-2022
Kerecis Limited $1,444.46 2024-2025 Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide
Sientra, INC. $1,212.09 2019-2022
Depuy Synthes Sales INC. $824.15 2019-2025 Trumatch, Matrixrib
Davol INC. $785.43 2019-2025 Phasix Mesh
Organogenesis INC. $633.53 2024-2025 Cygnus Matrix, Nushield
Abbvie INC. $615.52 2023-2025 Natrelle Saline-Filled Breast Implants, Strattice Reconstructive Tissue Matrix Bps
Show all 37 companies
CompanyGeneral paymentsYearsTop products
Sanara Medtech INC. $418.06 2022-2023 Celleraterx
Baxter Healthcare $294.75 2019-2022
Polynovo North America LLC $292.57 2024-2025 Novosorb Btm
Axogen $266.80 2023-2025 Avance Nerve Graft
Innovation Technologies INC $250.63 2022-2025 Irrisept
Aroa Biosurgery Incorporated $174.24 2024
Solventum Corporation $170.88 2025 Prevena
Bard Peripheral Vascular, INC. $164.94 2021
Surgical Theater. INC. $150.11 2025
Histosonics, INC. $146.49 2024
Avita Medical Americas, LLC $142.75 2025 Cohealyx, Recell, Permeaderm
Heron Therapeutics, INC. $122.93 2025 Zynrelef
Mimedx Group, INC. $84.20 2025
Conmed Corporation $70.96 2019
Ethicon US, LLC $70.15 2019
Kci USA, INC. $67.44 2019
Olympus America INC. $45.51 2020
Vioptix INC $39.04 2019
Smith+Nephew, INC. $26.59 2023 Pico 7, Renasys Go V2 Home, Renasys Touch
Stryker Corporation $26.17 2019
Aesculap, INC. $13.57 2024 Aesculap
Rti Surgical, INC $8.42 2023

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jesse Selber

$180,562.77

in general payments reported 2019-2025

Years
2019-2025
Top company
Integra Lifesciences Corporation
Context
The $20K reported for 2025 was more than what 97% of Plastic Surgery providers received nationally (typical 2025 total: $380).

https://glasscript.com/doctor/200021/jesse-selber

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.